Edwards Lifesciences Corporation
EW
$85.98
-$1.56-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.10B | 1.07B | 1.37B | 1.08B | 1.11B |
| Total Depreciation and Amortization | 160.90M | 156.60M | 156.60M | 117.40M | 118.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 308.20M | 210.50M | 55.10M | 4.40M | -94.20M |
| Change in Net Operating Assets | -206.70M | 154.60M | -562.80M | -755.50M | -610.20M |
| Cash from Operations | 1.36B | 1.60B | 1.02B | 794.90M | 876.20M |
| Capital Expenditure | -269.10M | -260.20M | -212.60M | -155.10M | -191.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -35.10M | -- | -298.20M | -298.20M | -298.20M |
| Divestitures | 42.50M | 42.50M | 3.93B | 3.93B | 3.93B |
| Other Investing Activities | -629.30M | -495.20M | -4.51B | -4.14B | -3.80B |
| Cash from Investing | -891.00M | -712.90M | -1.09B | 2.04B | 2.34B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 193.10M | 174.10M | 170.40M | 135.70M | 132.80M |
| Repurchase of Common Stock | -1.11B | -893.40M | -852.90M | -314.20M | -466.80M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -236.50M | -237.50M | -234.30M | 1.80M | 8.00M |
| Cash from Financing | -1.15B | -956.80M | -916.80M | -1.15B | -1.30B |
| Foreign Exchange rate Adjustments | -18.90M | -44.80M | 2.70M | 3.70M | 62.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -701.30M | -119.30M | -988.60M | 1.63B | 1.92B |